What Causes an Icteric Sample in Blood Tests?

An icteric sample is a blood specimen that has turned visibly yellow or deep amber because it contains too much bilirubin, the pigment produced when the body breaks down old red blood cells. When a lab flags a sample as “icteric,” it is not diagnosing a disease but describing a physical property of the blood that can interfere with accurate test results. The underlying cause is almost always elevated bilirubin from one of three broad categories: excessive red blood cell destruction, liver dysfunction, or a blockage in the bile ducts. Understanding what drives bilirubin up, and what the lab flag actually means for your results, clears up a lot of the confusion patients feel when they see the term on a report.

How Bilirubin Gets Into Your Blood

Bilirubin is a natural byproduct of hemoglobin recycling. Red blood cells live roughly 120 days. When they reach the end of their lifespan, the spleen and liver break them down. The heme component of hemoglobin is metabolized by an enzyme called heme oxygenase into iron, carbon monoxide, and a green pigment called biliverdin, which is then quickly converted into bilirubin by another enzyme.¹ This freshly made bilirubin is called unconjugated or “indirect” bilirubin. It travels through the bloodstream bound to albumin until the liver picks it up, attaches a sugar molecule to make it water-soluble (now called conjugated or “direct” bilirubin), and excretes it into bile. Bile flows into the intestines, where bilirubin gives stool its characteristic brown color.

When any step in this chain is disrupted, bilirubin accumulates in the blood. The more bilirubin present, the more intensely yellow the serum becomes. Normal total bilirubin in adults sits below about 1.2 mg/dL. Once levels climb past roughly 2 to 3 mg/dL, the yellow tint becomes obvious to the naked eye, and above that threshold, automated lab analyzers start to flag the sample as icteric.

Too Many Red Blood Cells Breaking Down

The first major category of causes involves the production side of the equation: bilirubin is generated faster than the liver can clear it. This happens when red blood cells are destroyed in unusually large numbers, a process called hemolysis. The liver is remarkably efficient at processing bilirubin under normal conditions, but when red cell turnover spikes, the incoming load overwhelms its capacity. Because the excess bilirubin has not yet been processed by the liver, it is almost entirely unconjugated.

Conditions that drive hemolysis include autoimmune hemolytic anemia (where the immune system attacks its own red cells), sickle cell disease, thalassemia, certain infections like malaria, mechanical destruction from artificial heart valves, and reactions to blood transfusions. Some medications and toxins also trigger red cell breakdown. In each case, the clinical picture usually involves a combination of anemia, elevated unconjugated bilirubin, and often a rise in lactate dehydrogenase, a marker of cell damage. The resulting icteric sample reflects genuine disease activity rather than a lab quirk.

When the Liver Cannot Keep Up

The liver sits at the center of bilirubin metabolism. It takes up unconjugated bilirubin from the blood, conjugates it, and exports it into bile. Damage to liver cells from any cause reduces the number of functioning hepatocytes and can impair both the uptake of unconjugated bilirubin from plasma and the transport and clearance of conjugated bilirubin through the bile ducts.² That means hepatic causes tend to raise both forms of bilirubin at once, which is one way clinicians differentiate liver-related jaundice from hemolysis.

Common liver conditions that lead to icteric samples include viral hepatitis (A, B, C, and E), alcoholic liver disease, drug-induced liver injury from acetaminophen or other medications, cirrhosis from any cause, and infiltrative diseases. Acute liver failure, such as from a massive acetaminophen overdose, can push bilirubin levels dramatically high in a matter of days. Chronic liver diseases tend to produce a more gradual rise. In either scenario, the yellow tint of the blood sample reflects compromised liver function.

Gilbert Syndrome and Other Genetic Variations

Not every icteric sample points to serious disease. Gilbert syndrome is an inherited condition affecting roughly 5 to 10 percent of the general population, and it is the single most common genetic cause of mildly elevated bilirubin. People with Gilbert syndrome carry a variation in the gene that controls the enzyme responsible for conjugating bilirubin in the liver. Specifically, an extra repeat in the promoter region of the UGT1A1 gene significantly reduces the enzymatic activity of that enzyme, slowing conjugation.³ The result is unconjugated bilirubin that drifts above normal, usually in the 1.5 to 3 mg/dL range, and can climb higher during fasting, stress, or illness.

Gilbert syndrome is benign and requires no treatment, but it can catch people off guard. A person who fasts before routine blood work, exercises heavily the day before, or is fighting a mild illness may produce a sample that the lab flags as icteric. If the rest of the liver panel looks normal and there is no anemia, Gilbert syndrome is usually the explanation. Other, rarer inherited conditions like Crigler-Najjar syndrome cause far more severe bilirubin elevation, but these are typically identified in infancy.

Sepsis and Critical Illness

In hospitalized patients, especially those in intensive care, icteric samples often arise from sepsis-induced cholestasis. Sepsis triggers a cascade of inflammation that directly impairs the liver’s ability to handle bile and bilirubin. Inflammatory molecules like tumor necrosis factor-alpha and interleukin-1 beta reduce the expression of key transport proteins in liver cells, diminishing both the uptake of bile salts from the blood and the export of bilirubin into bile. The result is a backup of conjugated bilirubin into the bloodstream, combined with reduced bile flow.⁴ Hypoxia and poor blood flow to the liver during sepsis make this worse. For ICU teams, a rising bilirubin is both a marker of disease severity and a practical headache, because the icteric sample may interfere with the very lab tests they need to guide treatment.

Bile Duct Obstruction

The third broad cause is post-hepatic: something physically blocks the flow of bile after the liver has done its job. The most common culprits are gallstones lodged in the common bile duct and tumors of the pancreatic head or bile duct itself. When bile cannot drain into the intestines, conjugated bilirubin backs up into the bloodstream. Because this bilirubin is already water-soluble, it spills into the urine, turning it dark brown or tea-colored, while stool becomes pale because it is no longer receiving the pigment. The serum sample from such a patient can be intensely yellow or even greenish.

Obstruction-related icterus tends to produce the highest bilirubin levels, sometimes exceeding 20 or 30 mg/dL. In the lab, these samples can cause the most severe interference with other tests. The clinical context usually makes the cause obvious: the patient has abdominal pain, dark urine, and imaging that shows a dilated bile duct. But occasionally, a slowly growing tumor causes a painless, insidious rise in bilirubin that first appears as an unexpected icteric flag on routine blood work.

What the Lab Actually Does When a Sample Is Icteric

Modern automated chemistry analyzers do not rely on a technician squinting at a tube. They measure what is called the icteric index, a quantitative or semi-quantitative estimate of the bilirubin concentration in the sample based on its optical properties. Some analyzers report this as a continuous number, while others categorize it into graded levels.⁵ The analyzer compares the icteric index against threshold values specific to each assay. If the bilirubin level in the sample is high enough to potentially distort a particular test, that test result gets flagged or suppressed entirely.

This system is part of a broader quality check known as HIL (hemolysis, icterus, lipemia), which screens every sample for three common endogenous interferences. Each has its own optical signature. Hemolysis turns samples red or pink from free hemoglobin; lipemia makes them milky from excess fat particles; and icterus makes them yellow from bilirubin. Because these pigments absorb light at specific wavelengths, they can skew any test that relies on photometric measurement, which is most of clinical chemistry.

Which Tests Get Distorted and How

The practical consequence of an icteric sample is that certain test results cannot be trusted. Bilirubin absorbs light most strongly in the blue range of the visible spectrum, around 450 to 460 nanometers. Any assay that measures a color change in a similar wavelength range is vulnerable. The interference can push results either falsely high or falsely low, depending on the assay chemistry.

Creatinine and total protein are particularly affected. Icteric interference can produce falsely low readings for both of these tests, a problem that diluting the sample does not reliably fix.⁶ A falsely low creatinine is clinically dangerous because it can mask kidney dysfunction, making a patient appear to have better kidney function than they actually do. In one large-scale analysis, the icteric index exceeded assay-specific interference thresholds in about 0.14% of all clinical chemistry tests. Although that sounds tiny, creatinine alone was affected in roughly 0.6% of samples, and total protein in about 2.2%, while ammonia was flagged in nearly 4% of tests.⁷ In a busy hospital lab running thousands of tests a day, those percentages add up to a meaningful number of unreliable results.

Other commonly affected assays include lipase, cholesterol panels, certain drug levels, and some immunoassays. The direction and magnitude of the interference vary by platform and reagent, which is one reason different hospitals may have slightly different policies on when to flag or reject icteric samples.

What Happens to a Flagged Sample

When a sample trips the icteric threshold for a given test, the lab has limited options. Often, the choice comes down to diluting the sample and re-running the assay or simply rejecting that test and reporting no result.⁸ Dilution can work for some assays but not all, and it introduces its own risk of inaccuracy, especially for analytes present at low concentrations. Rejection is the safer default for the patient but frustrating for the clinical team, which needs those results to make treatment decisions.

A newer approach involves photoisomerization, a technique that uses light to convert bilirubin into a form that no longer absorbs in the problematic wavelength range. Devices designed for this purpose expose the sample to specific wavelengths of light, shifting bilirubin into water-soluble isomers that do not interfere with photometric assays. This concept is well established in neonatal medicine, where phototherapy is used to treat jaundice in newborns, but applying it to laboratory samples is a more recent development. Early results are promising, though such devices are not yet standard in most clinical labs.

Pre-Analytical Factors That Affect Bilirubin in the Tube

The icteric index of a sample does not always perfectly reflect what was happening in the patient’s bloodstream at the moment of the draw. How the sample is handled afterward matters. Bilirubin is sensitive to light. In samples with elevated bilirubin left at room temperature and exposed to ambient light, total bilirubin dropped by about 9% after 24 hours and roughly 18% after 48 hours. Direct bilirubin showed similar declines.⁹ In samples with normal bilirubin levels, the absolute changes were smaller but proportionally significant: total bilirubin fell by nearly half over 48 hours of light exposure at room temperature.

This means a sample left sitting on a bench near a window or under fluorescent lights will read less icteric than it truly was. For most routine chemistry, this is a minor concern because labs process samples quickly. But in scenarios where there is a delay, such as samples transported between facilities, the icteric index at the time of analysis may underestimate the true bilirubin concentration. Wrapping tubes in foil or keeping them in opaque containers during transport helps preserve accuracy. Temperature also plays a role: refrigeration slows bilirubin degradation compared to room temperature storage.

Icteric Samples in Newborns

Newborn blood samples are icteric far more often than adult samples. Nearly all newborns develop some degree of jaundice in the first week of life, because their immature livers are not yet efficient at conjugating bilirubin and because they have a higher rate of red blood cell turnover relative to body size. In most cases, this “physiological jaundice” peaks around day three to five and resolves on its own. Breastfeeding jaundice, caused by inadequate caloric intake in the first days, and breast milk jaundice, caused by substances in breast milk that slow bilirubin clearance, can extend the timeline.

For neonatal labs, icteric interference is a constant headache rather than an occasional one. Bilirubin levels in a jaundiced newborn can easily exceed 15 to 20 mg/dL, pushing the sample far past the interference thresholds for many common assays. This is particularly problematic because sick newborns need frequent lab monitoring. Neonatal units typically have protocols in place to manage this, including using assay platforms that are less susceptible to icteric interference and employing alternative methods like blood gas analyzers for certain electrolytes.

When Yellow Blood Is Not Bilirubin

Occasionally, a sample appears yellow for reasons that have nothing to do with bilirubin. Carotenemia, caused by eating large amounts of beta-carotene-rich foods like carrots, sweet potatoes, and squash, can tint the blood serum yellow-orange. Unlike bilirubin-driven icterus, carotenemia does not turn the whites of the eyes yellow because carotenoids deposit preferentially in skin and fat rather than in the sclera. The distinction matters clinically because carotenemia is harmless and does not indicate liver disease, but visually it can fool a manual inspection. Modern analyzers distinguish the two because carotenoids and bilirubin absorb light at slightly different wavelengths, though older equipment may not discriminate as well.

Certain drugs can also tint plasma. High-dose rifampin, a tuberculosis antibiotic, turns body fluids orange. Doxorubicin, a chemotherapy agent, can cause a reddish-orange hue. These pigments can confuse the icteric index on some platforms, though most modern analyzers are calibrated to minimize false flags from drug-related discoloration. When a sample is flagged icteric but the clinical context does not support elevated bilirubin, lab scientists will sometimes measure bilirubin directly to confirm whether the flag reflects true icterus.

What You Can and Cannot Do About an Icteric Sample

If you are a patient and your lab report mentions an icteric sample, the first thing to understand is that it is not a diagnosis. It is a description of your blood’s appearance at the time it was drawn. The clinical question is why your bilirubin was elevated. If you have known liver disease, hemolytic anemia, or a bile duct issue, the icteric flag is unsurprising and simply confirms that your bilirubin is up. If the flag appears unexpectedly on routine blood work and your other liver markers are normal, Gilbert syndrome is the most likely explanation, especially if you fasted before the draw or were under physical stress.

You cannot prevent your blood from being icteric if you have a condition that raises bilirubin. What you can do is make sure your clinician knows about any potentially interfering conditions so that flagged results are interpreted in context rather than taken at face value. If a critical test like creatinine is suppressed due to icteric interference, your doctor can order an alternative method that is less susceptible to the interference, or request that the lab use a different analytical platform. In most cases, the lab itself will catch the problem and either provide a corrected result or note that the value should be interpreted with caution.

Icteric Interference in the Era of Point-of-Care Testing

Point-of-care devices, the small portable analyzers used in emergency departments, ambulances, and clinics, handle icterus with varying degrees of sophistication. Central laboratory analyzers routinely screen every sample for hemolysis, icterus, and lipemia before reporting results, but many point-of-care devices lack this built-in check. A handheld meter measuring glucose or electrolytes from a fingerstick may not recognize that the sample is icteric and could report a number without any interference flag. This is a known gap in point-of-care quality assurance.

Some newer point-of-care platforms have added optical screening, but the technology is not yet universal. In practice, this means that a clinician using a bedside device on a visibly jaundiced patient should mentally apply the same skepticism that a central lab applies automatically. When the clinical picture does not match the point-of-care result, confirming with a central lab draw is a reasonable precaution. For critically ill patients with deep jaundice, some institutions default to central lab testing for analytes known to be affected by bilirubin, even when point-of-care options are available.